Anna on for Yasmeen Rahimi's questions to Cytokinetics Inc (CYTK) leadership • Q2 2025
Question
An analyst on for Yasmeen Rahimi at Piper Sandler asked about expectations for potential differences in the REMS program between the U.S. and the EU and their implications.
Answer
President and CEO Robert Blum explained that while the EU lacks a formal REMS mechanism, risk mitigation is handled via labeling. He anticipates more similarities than differences between the regions, as the drug was studied internationally and discussions with both the FDA and EMA are tracking similarly.